US Patent

US11400077 — Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders

Method of Use · Assigned to Ocuphire Pharma Inc · Expires 2039-10-25 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions using phentolamine mesylate to treat presbyopia, mydriasis, and other ocular disorders.

USPTO Abstract

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

Drugs covered by this patent

phentolamine-mesylate (PHENTOLAMINE MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3804`	—	phentolamine-mesylate

Patent Metadata

Patent number: US11400077
Jurisdiction: US
Classification: Method of Use
Expires: 2039-10-25
Drug substance claim: No
Drug product claim: No
Assignee: Ocuphire Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.